drugset / Trial / NCT00047489
Study of ABT-751 in Patients With Refractory Hematologic Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
ABT-751 is a new antitumor drug that that interferes with cell division. The goal of this clinical research study is to find the highest safe dose of ABT-751 that can be given as a treatment for refractory hematologic malignancies. The safety and side effects of ABT-751 will also be studied.
Timeline
- Start
- 2002-12
- Primary completion
- 2005-01
- Completion
- 2005-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABT-751 | Other / unclassified | — | Oral |